Inhibition of arterial lesion progression in CD16-deficient mice: Evidence for altered immunity and the role of IL-10

Cardiovascular Research

Volumn 85, Issue 1, 2010, Pages 224-231

  Kelly, John A ^a,b   Griffin, Mary E ^a,b   Fava, Roy A ^a,b   Wood, Sheryl G ^a,b   Bessette, Katherine A ^a,b   Miller, Elizabeth R ^c   Huber, Sally A ^d   Binder, Christoph J ^c,e   Witztum, Joseph L ^c   Morganelli, Peter M ^a,b  

^a VA MEDICAL CENTER   (United States)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF VERMONT   (United States)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

CD16; Fc receptors; IL 10; Interferon; Lesions; Lymphoid follicle; Murine atherosclerosis; Oxidized LDL; T cells

Indexed keywords

CD16 ANTIGEN; CD8 ANTIGEN; FC RECEPTOR; GAMMA INTERFERON; IMMUNOGLOBULIN G1; INTERLEUKIN 10; INTERLEUKIN 4; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA ROOT; ARTERY LESION; ARTICLE; ATHEROGENESIS; BRACHIOCEPHALIC TRUNK; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; IMMUNE DEFICIENCY; KNOCKOUT MOUSE; LIPID BLOOD LEVEL; LIPID DIET; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION;

ANIMALS; ARTERIES; ATHEROSCLEROSIS; AUTOANTIBODIES; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; FEMALE; IMMUNITY; INTERFERON-GAMMA; INTERLEUKIN-10; LIPIDS; LIPOPROTEINS, LDL; MALE; MICE; RECEPTORS, IGG; RECEPTORS, LDL;

EID: 72049087786     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvp300     Document Type: Article

References (52)

1. Binder CJ, Chang MK, Shaw PX, Miller YI, Hartvigsen K, Dewan A et al. Innate and acquired immunity in atherogenesis. Nat Med 2002;8:1218-1226.
2. Caligiuri G, Nicoletti A, Poirier B, Hansson GK. Protective immunity against atherosclerosis carried by B cells of hypercholesterolemic mice. J Clin Invest 2002;109: 745-753.
3. Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat Rev Immunol 2006;6:508-519.
4. Major AS, Fazio S, Linton MF. B-lymphocyte deficiency increases atherosclerosis in LDL receptor-null mice. Arterioscler Thromb Vasc Biol 2002;22:1892-1898.
5. Osterud B, Bjorklid E. Role of monocytes in atherogenesis. Physiol Rev 2003;83: 1069-1112.
6. + T-cell priming efficacy under hypercholesterolemic conditions associated with atherosclerosis. Circ Res 2008;103:965-973.
7. Sun J, Sukhova GK, Wolters PJ, Yang M, Kitamoto S, Libby P et al. Mast cells promote atherosclerosis by releasing proinflammatory cytokines. Nat Med 2007;13:719-724.
8. Swirski FK, Pittet MJ, Kircher MF, Aikawa E, Jaffer FA, Libby P et al. Monocyte accumulation in mouse atherogenesis is progressive and proportional to extent of disease. Proc Natl Acad Sci USA 2006;103:10340-10345.
9. Weber C, Zernecke A, Libby P. The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. Nat Rev Immunol 2008; 8:802-815.
10. Whitman SC, Rateri DL, Szilvassy SJ, Yokoyama W, Daugherty A. Depletion of natural killer cell function decreases atherosclerosis in low-density lipoprotein receptor null mice. Arterioscler Thromb Vasc Biol 2004;24:1049-1054.
11. Zhou X, Stemme S, Hansson GK. Evidence for a local immune response in atherosclerosis. CD4+ T cells infiltrate lesions of apolipoprotein-E-deficient mice. Am J Pathol 1996;149:359-366.
12. Huber SA, Sakkinen P, David C, Newell MK, Tracy RP. T helper-cell phenotype regulates atherosclerosis in mice under conditions of mild hypercholesterolemia. Circulation 2001;103:2610-2616.
13. 4+T cells reactive to modified low-density lipoprotein aggravates atherosclerosis. Arterioscler Thromb Vasc Biol 2006;26:864-870.
14. Gotsman I, Grabie N, Gupta R, Dacosta R, MacConmara M, Lederer J et al. Impaired regulatory T-cell response and enhanced atherosclerosis in the absence of inducible costimulatory molecule. Circulation 2006;114:2047-2055.
15. Laurat E, Poirier B, Tupin E, Caligiuri G, Hansson GK, Bariety J et al. In vivo down-regulation of T helper cell 1 immune responses reduces atherogenesis in apolipo-protein E-knockout mice. Circulation 2001;104:197-202.
16. Binder CJ, Horkko S, Dewan A, Chang MK, Kieu EP, Goodyear CS et al. Pneumo-coccal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat Med 2003;9: 736-743.
17. Hartvigsen K, Chou MY, Hansen LF, Shaw PX, Tsimikas S, Binder CJ et al. The role of innate immunity in atherogenesis. J Lipid Res 2009;50:s388-393.
18. Binder CJ, Hartvigsen K, Chang MK, Miller M, Broide D, Palinski W et al. IL-5 links adaptive and natural immunity specific for epitopes of oxidized LDL and protects from atherosclerosis. J Clin Invest 2004;114:427-437.
19. Mironova M, Virella G, Lopes-Virella MF. Isolation and characterization of human antioxidized LDL autoantibodies. Arterioscler Thromb Vasc Biol 1996;6:222-229.
20. Palinski W, Miller E, Witztum JL. Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc Natl Acad Sci USA 1995;92:821-825.
21. Palinski W, Ord VA, Plump AS, Breslow JL, Steinberg D, Witztum JL. ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis. Demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to malondialdehyde-lysine in serum. Arterioscler Thromb 1994;14:605-616.
22. Yla-Herttuala S, Palinski W, Butler SW, Picard S, Steinberg D, Witztum JL. Rabbit and human atherosclerotic lesions contain IgG that recognizes epitopes of oxidized LDL. Arterioscler Thromb 1994;14:32-40.
23. Hernandez-Vargas P, Ortiz-Munoz G, Lopez-Franco O, Suzuki Y, Gallego-Delgado J, Sanjuan G et al. Fcgamma receptor deficiency confers protection against atherosclerosis in apolipoprotein E knockout mice. Circ Res 2006;99: 188-1196.
24. Poole A, Gibbins JM, Turner M, van Vugt MJ, van de Winkel JG, Saito T et al. The Fc receptor gamma-chain and the tyrosine kinase Syk are essential for activation of mouse platelets by collagen. EMBO J 1997;16:2333-2341.
25. Qian D, Sperling AI, Lancki DW, Tatsumi Y, Barrett TA, Bluestone JA et al. The gamma chain of the high-affinity receptor for IgE is a major functional subunit of the T-cell antigen receptor complex in gamma delta T lymphocytes. Proc Natl Acad Sci USA 1993;90:11875-11879.
26. Rodewald HR, Arulanandam AR, Koyasu S, Reinherz EL. The high affinity Fc epsilon receptor gamma subunit (Fc epsilon RI gamma) facilitates T cell receptor expression and antigen/major histocompatibility complex-driven signaling in the absence of CD3 zeta and CD3 eta. J Biol Chem 1991;266:15974-15978.
27. Takai T, Li M, Sylvestre D, Clynes R, Ravetch JV. FcR gamma chain deletion results in pleiotrophic effector cell defects. Cell 1994;76:519-529. (Pubitemid 24064172)
28. Hirano M, Davis RS, Fine WD, Nakamura S, Shimizu K, Yagi H et al. IgEb immune complexes activate macrophages through FcgammaRIV binding. Nat Immunol 2007;8:762-771.
29. Hulett MD, Hogarth PM. Molecular basis of Fc receptor function. Adv Immunol 1994;57:1-127.
30. Hazenbos WL, Heijnen IA, Meyer D, Hofhuis FM, Renardel de Lavalette CR, Schmidt RE et al. Murine IgG1 complexes trigger immune effector functions predominantly via Fc gamma RIII (CD16). J Immunol 1998;161:3026-3032.
31. Bandukwala HS, Clay BS, Tong J, Mody PD, Cannon JL, Shilling RA et al. Signaling through FcfgammagRIII is required for optimal T helper type (Th)2 responses and Th2-mediated airway inflammation. J Exp Med 2007;284:1875-1889.
32. Hazenbos WL, Gessner JE, Hofhuis FM, Kuipers H, Meyer D, Heijnen IA et al. Impaired IgG-dependent anaphylaxis and Arthus reaction in FcgRIII (CD16) deficient mice. Immunity 1996;5:181-188.
33. Lynch RG, Hagen M, Mueller A, Sandor M. Potential role of Fc gamma R in early development of murine lymphoid cells: evidence for functional interaction between Fc gamma R on pre-thymocytes and an alternative, non-Ig ligand on thymic stromal cells. Immunol Lett 1995;44:105-109.
34. Sandor M, Galon J, Takacs L, Tatsumi Y, Mueller AL, Sautes C et al. An alternative Fc gamma-receptor ligand: potential role in T-cell development. Proc Natl Acad Sci USA 1994;91:12857-12861.
35. Plump AS, Masucci-Magoulas L, Bruce C, Bisgaier CL, Breslow JL, Tall AR. Increased atherosclerosis in ApoE and LDL receptor gene knock-out mice as a result of human cholesteryl ester transfer protein transgene expression. Arterios-cler Thromb Vasc Biol 1999;19:1105-1110.
36. Bird DA, Gillotte KL, Horkko S, Friedman P, Dennis EA, Witztum JL et al. Receptors for oxidized low-density lipoprotein on elicited mouse peritoneal macro-phages can recognize both the modified lipid moieties and the modified protein moieties: implications with respect to macrophage recognition of apopto-tic cells. Proc Natl Acad Sci USA 1999;96:6347-6352.
37. Moos MP, John N, Grabner R, Nossmann S, Gunther B, Vollandt R et al. The lamina adventitia is the major site of immune cell accumulation in standard chow-fed apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2005;25: 2386-2391.
38. Uyemura K, Demer LL, Castle SC, Jullien D, Berliner JA, Gately MK et al. Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis. J Clin Invest 1996;97:2130-2138.
39. Pinderski Oslund LJ, Hedrick CC, Olvera T, Hagenbaugh A, Territo M, Berliner JA et al. Interleukin-10 blocks atherosclerotic events in vitro and in vivo. Arterioscler Thromb Vasc Biol 1999;19:2847-2863.
40. Liu Y, Li D, Chen J, Xie J, Bandyopadhyay S, Zhang D et al. Inhibition of atherogen-esis in LDLR knockout mice by systemic delivery of adeno-associated virus type 2-hIL-10. Atherosclerosis 2006;188:19-27.
41. Pinderski LJ, Fischbein MP, Subbanagounder G, Fishbein MC, Kubo N, Cheroutre H et al. Overexpression of interleukin-10 by activated T lymphocytes inhibits atherosclerosis in LDL receptor-deficient mice by altering lymphocyte and macrophage phenotypes. Circ Res 2002;90:1064-1071.
42. Mallat Z, Besnard S, Duriez M, Deleuze V, Emmanuel F, Bureau MF et al. Protective role of interleukin-10 in atherosclerosis. Circ Res 1999;85:e17-e24.
43. Caligiuri G, Rudling M, Ollivier V, Jacob MP, Michel JB, Hansson GK et al. Interleukin-10 deficiency increases atherosclerosis, thrombosis, and low-density lipoproteins in apolipoprotein E knockout mice. Mol Med 2003;9:10-17.
44. Flamand V, Shores EW, Tran T, Huang K, Lee E, Grinberg A et al. Delayed maturation of CD4-CD8-Fc gamma RII/III+ T and natural killer cell precursors in Fc epsilon RI gamma transgenic mice. J Exp Med 1996;184:1725-1735.
45. Pinheiro da Silva F, Aloulou M, Skurnik D, Benhamou M, Andremont A, Velasco IT et al. CD16 promotes Escherichia coli sepsis through an FcR gamma inhibitory pathway that prevents phagocytosis and facilitates inflammation. Nat Med 2007; 13:1368-1374.
46. Gupta S, Pablo AM, Jiang X, Wang N, Tall AR, Schindler C. IFN-gamma potentiates atherosclerosis in ApoE knock-out mice. J Clin Invest 1997;99:2752-2761.
47. Tellides G, Tereb DA, Kirkiles-Smith NC, Kim RW, Wilson JH, Schechner JS et al. Interferon-gamma elicits arteriosclerosis in the absence of leukocytes. Nature 2000;403:207-211. (Pubitemid 30050965)
48. Whitman SC, Ravisankar P, Daugherty A. IFN-gamma deficiency exerts gender-specific effects on atherogenesis in apolipoprotein E-/-mice. J Interferon Cytokine Res 2002;22:661-670.
49. Whitman SC, Ravisankar P, Elam H, Daugherty A. Exogenous interferon-gamma enhances atherosclerosis in apolipoprotein E-/-mice. Am J Pathol 2000;157: 1819-1824.
50. Buono C, Come CE, Stavrakis G, Maguire GF, Connelly PW, Lichtman AH. Influence of interferon-gamma on the extent and phenotype of diet-induced atherosclerosis in the LDLR-deficient mouse. Arterioscler Thromb Vasc Biol 2003;23: 454-460.
51. Potteaux S, Esposito B, van Oostrom O, Brun V, Ardouin P, Groux H et al. Leukocyte-derived interleukin 10 is required for protection against atherosclerosis in low-density lipoprotein receptor knockout mice. Arterioscler Thromb Vasc Biol 2004;24:1474-1478.
52. 4+ T cells for IL-4 production. J Exp Med 2004;199: 1619-1630.